<DOC>
	<DOCNO>NCT01684241</DOCNO>
	<brief_summary>Clinical first-in-human dose escalation study evaluate safety tolerability intranodal administration RNA-based cancer vaccine target two tumor-associated antigen patient advance melanoma</brief_summary>
	<brief_title>RBL001/RBL002 Phase I Clinical Trial</brief_title>
	<detailed_description>RBL001/RBL002 naked ribonucleic acid ( RNA ) base recombinant vaccine optimize induce antigen specific CD8+ CD4+ T cell response malignant melanoma target antigen . The Targeted antigen well characterize antigen melanoma previously utilized excellent safety proven immunogenicity vaccine target number independent clinical trial . The overall rationale study determine safety novel RNA base vaccine approach determine vaccine target antigen direct immune response early biomarkers clinical mode action . The RBL001/RBL002 vaccine expect lead several effect contribute immunological ( therapeutic ) effect . First , ultrasound guide administration naked RNA drug product lymph node expect result rapid uptake naked RNA lymph node resident professional antigen-presenting cell ( APCs ) . Incorporated RNA know translocate cytoplasm lead translation host ribosome complex respective protein antigen . The recombinant vaccine optimize immunogenicity enable presentation diverse antigenic epitopes HLA-class I well HLA-class II molecule . Consecutively , antigen-specific CD8+ CD4+ T cell response trigger HLA-peptide complex surface antigen present cell . In addition , RNA administration also lead transient activation ( change surface marker expression cytokine secretion ) APCs target lymph node particularly via signal TLR 7 8 leading adjuvant effect , support induction target-specific T cell response systemic anti-tumor activity .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Stage IIC , IIIAC unresectable stage IV cutaneous melanoma ( AJCC 2009 melanoma classification ) First line therapy subject eligible decline first line therapy available treatment option transparently disclose ( documented ! ) Antigen expression confirm RTPCR analysis FFPE ≥ 18 year age Written inform consent ( part I part II ) ECOG performance status ( PS ) 01 Karnofsky Index 70100 % Life expectancy &gt; 3 month WBC ≥ 3x109/L Hemoglobin ≥ 10 g/dl Platelet count ≥ 100,000/mm³ LDH level &lt; 2.0 x ULN Negative pregnancy test ( measure βHCG ) females childbearing age Suitable lymph node injection use ultrasound guidance Pregnancy breastfeed Primary ocular melanoma Presence history ( &lt; 5 year ) second malignancy squamous basal cell carcinoma , nonactive prostate cancer cervical carcinoma situ Brain metastases Known symptomatic pleural effusion and/or ascites Known hypersensitivity active substance excipients A serious local infection ( e. g. cellulitis , abscess ) systemic infection ( e. g. pneumonia , septicemia ) require systemic antibiotic treatment within 2 week prior first dose study medication Acute chronic active hepatitis B C infection , EBV CMV Receipt allogenic stem cell transplantation Clinically relevant autoimmune disease Systemic immune suppression : HIV disease Use chronic oral systemic steroid medication ( topical inhalational steroid permit ) Other clinical relevant systemic immune suppression Symptomatic congestive heart failure ( NYHA 3 4 ) Unstable angina pectoris Radiotherapy , chemotherapy , major surgery , immunotherapy , vaccination , concurrent anticancer therapy investigational drug within 28 day first treatment study Minor surgery within 14 day first treatment study Treatment Ipilimumab within 84 day first treatment study Fertile male females unwilling employ adequate mean contraception ( e. g. condom spermicide , diaphragm spermicide , birth control pill , injection , patch intrauterine device ) study treatment 28 day last dose study treatment Presence serious concurrent illness condition ( e. g. psychological , family , sociological , geographical circumstance ) permit adequate followup compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Biontech</keyword>
	<keyword>Biontech RNA Pharmaceuticals GmbH</keyword>
	<keyword>Biontech RNA</keyword>
	<keyword>MERIT</keyword>
	<keyword>RNA</keyword>
	<keyword>Immuno Therapy</keyword>
	<keyword>RB_0001-01</keyword>
	<keyword>Ribological</keyword>
	<keyword>Melanoma</keyword>
	<keyword>RBL001</keyword>
	<keyword>RBL002</keyword>
	<keyword>cancer vaccine</keyword>
</DOC>